Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05452304
Other study ID # D9690C00001
Secondary ID 2022-001438-12
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 12, 2022
Est. completion date September 5, 2024

Study information

Verified date May 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn's disease.


Description:

This is a Phase I, randomised, double-blind, placebo controlled study in healthy male and female subjects as well as patients with Crohn's disease performed at a single study centre. This study is comprised of 3 parts: Part 1 (sub-parts 1a and 1b), Part 2, and Part 3 (sub-Parts 3a and 3b). - Part 1a: This is a First-In-Human (FIH), single ascending dose (SAD) sequential group study. Up to 7 dose levels of AZD7798 are planned to be investigated. Depending on the findings, an additional dose may be added. Up to 80 healthy subjects are planned to be included. Eight subjects will participate in each single dose cohort. Within each cohort, 6 subjects will be randomised to receive AZD7798, and 2 subjects will be randomised to receive placebo. Each subject will be enrolled up to 113 days (approximately 16 weeks). - Part 1b: Up to 8 subjects will be randomised to receive a planned dose of AZD7798 (up to 6 subjects) or placebo (up to 2 subjects) on Day 1 and Day 15. This cohort is planned to start after completion of the single dose level cohort in Part 1a. Each subject will be enrolled up to 149 days (approximately 21 weeks). - Part 2: Up to 8 patients will be randomised (2:1:1) into 1 of 3 strata and receive: - Stratum 1: AZD7798 on Day 1 and Day 15 (up to 4 patients). - Stratum 2: Placebo on Day 1 and AZD7798 on Day 15 (up to 2 patients). - Stratum 3: AZD7798 on Day 1 and placebo on Day 15 (up to 2 patients). Each subject will be enrolled up to 149 days (approximately 21 weeks). - Part 3: Subjects will be randomised to AZD7798 or placebo in a ratio of 3:1 (up to 6 subjects will receive AZD7798 and up to 2 subjects will receive placebo).


Recruitment information / eligibility

Status Recruiting
Enrollment 144
Est. completion date September 5, 2024
Est. primary completion date September 5, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: All Study Parts: - Provision of signed and dated, written informed consent prior to any study specific procedures. - Subjects must have suitable veins for cannulation or repeated venepuncture. - Males who are sexually active with a female partner of childbearing potential and who have not had a vasectomy must agree to comply with highly effective methods of contraception from the time of IMP administration until 4 months after the last dose of IMP. - Non-smoker, or mild smoker (no more than 10 cigarettes per day). - Have a BMI between 18 and 30 kg/m2 inclusive and weigh at least 45 kg and no more than 100 kg inclusive. - Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating. - Provision of signed, written and dated informed consent for optional genetic/biomarker research. - Evidence of completion of an appropriate vaccination regimen to SARS-CoV-2 at least 14 days prior to screening as appropriate and recommended in contemporaneous local, regional, or national guidelines. Part 1 (Healthy Subjects), Part 3a (Healthy Japanese Subjects) and Part 3b (Healthy Chinese Subjects): • Healthy male and female (of childbearing and non childbearing potential) subjects aged 18 to 50 years inclusive. Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease): - Male and female (of childbearing and non childbearing potential) patients with Crohn's disease aged 18 to 60 years inclusive. - Patients with confirmed Crohn's disease (diagnosed via endoscopy, histology and/or imaging) with onset of symptoms at least 3 months prior to screening. - Active disease, defined by at least one symptom and sign consistent with Crohn's disease AND at least one of the following: 1. CRP > 5mg/L at screening. 2. Faecal calprotectin > 250µg/g at screening. 3. Evidence of active inflammation on cross-sectional imaging within past 3 months prior to screening. 4. Evidence of active inflammation on endoscopy within past 3 months prior to screening. Part 3a (Japanese Subjects) • Subject is a native of Japan; defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan. Part 3b (Chinese Subjects) - Healthy Chinese subjects. Subjects of Chinese ancestry are eligible based on meeting all of the following: 1. Born in mainland China, Hong Kong, or Taiwan. 2. Descendants of 4 ethnic Chinese grandparents and 2 ethnic Chinese parents. 3. Have lived outside China for less than 10 years at the time of screening. Exclusion Criteria: All Study Parts: • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of Investigational Medicinal Product (IMP). • Any positive result on Screening for HBsAg, anti-HBc antibody, anti-HCV antibody, and HIV. • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or, history of hypersensitivity to drugs with a similar chemical structure or class to AZD7798. • For females of childbearing potential using hormonal contraception: Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP. • Subjects with a positive diagnostic nucleic acid test (using PCR) for SARS-CoV-2 prior to dosing. • Live or attenuated vaccine within 4 weeks of Visit 1 and until the end of the follow up period. - An active infection, or history of serious infection within the preceding 28 days. - Use of antibiotics within 28 days prior to the first administration of IMP. - History of symptomatic herpes simplex (excluding cold sores) or herpes zoster infection within 3 months prior to screening. - Positive or indeterminate TB QuantiFERON test. - Has received another new chemical entity within 30 days/5 half-lives of the first administration of IMP in this study. - Subjects who cannot communicate reliably with the Investigator. - Vulnerable subjects. Part 1 (Healthy Subjects), Part 3a (Japanese Subjects, and Part 3b (Chinese Subjects): • Any laboratory values with deviations. • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 20, as judged by the Investigator. • Abnormal vital signs, after 5 minutes supine rest at screening and admission. • Known or suspected history of drug abuse in the last 1 year as judged by the Investigator. • History of alcohol abuse or excessive intake of alcohol within the last 1 year. as judged by the Investigator. • Positive screen for drugs of abuse at screening or admission to the Clinical Unit or positive screen for alcohol on admission to the Clinical Unit prior to the first administration of the IMP. • Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate,) as judged by the Investigator. Part 1a (in case of dose escalation in patients) and Part 2 (Patients with Crohn's Disease): • Patients with any uncontrolled medical conditions, other than active Crohn's disease, that in the opinion of the Investigator put the patient at unacceptable risk or interfere with study assessments or integrity of the data. • Current diagnosis of ulcerative colitis, indeterminate colitis, inflammatory bowel disease-unclassified, infectious colitis, or ischaemic colitis. • History of CMV colitis 12 months prior to screening. • Patients with fulminant Crohn's disease or toxic megacolon. • Planned surgery for Crohn's disease prior to the end of study follow up visit. • Patients with symptomatic intestinal stenosis, known pre-stenotic dilatation, undrained fistula(e), or abscesses. • Initiation or change in dose of azathioprine or mercaptopurine (including initiation or discontinuation of allopurinol) within 4 weeks of the first administration of IMP. • Treatment with methotrexate, ciclosporin, tacrolimus or thalidomide within 4 weeks of the first administration of IMP. • Treatment with an anti-TNF biologic within 8 weeks of the first administration of IMP, unless therapeutic drug monitoring is performed and drug concentrations are undetectable. - Treatment with any biologic, other than an anti-TNF, within 12 weeks or with undetectable serum concentrations prior to the first administration of IMP, unless therapeutic drug monitoring is performed and drug concentrations are undetectable. - Treatment with rituximab within 12 months prior to the first administration of IMP. - Any laboratory values with deviations. - Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 49, as judged by the Investigator. - Abnormal vital signs, after 5 minutes supine rest, defined as any of the following at screening and admission. - Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12 lead ECG. - Unstable lifestyle factors, such as alcohol use to excess or recreational drug use, to the extent that in the opinion of the Investigator they would interfere with the ability of a patient to complete the study. - Current malignancy or history of malignancy.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AZD7798
Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
Placebo
Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.

Locations

Country Name City State
United Kingdom Research Site Harrow

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Parexel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse Events (AEs) The safety and tolerability of AZD7798 following administration of single ascending doses will be assessed. Until follow-up (Day 85) or Early termination (ET)
Secondary Area under plasma concentration time curve from zero to infinity (AUCinf) The AUCinf of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary AUClast The AUClast of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Maximum serum concentration (Cmax) The Cmax of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Time to reach maximum serum concentration (tmax) The tmax of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Time to last measurable concentration (tlast) The tlast of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Terminal elimination half-life (t½?z) The t½?z of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Systemic clearance (CL) The CL of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Apparent total clearance (CL/F) The CL/F of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Volume of distribution based on the terminal phase (Vz) The Vz of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Apparent volume of distribution based on terminal phase (Vz/F) The Vz/F of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Bioavailability (F) The F of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Volume of distribution at steady state (Vss) The Vss of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary AUClast/D The AUClast/D of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary AUCinf/D The AUCinf/D of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Cmax/D The Cmax/D of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
Secondary Percentage of patients with antidrug antibodies (ADAs) The immunogenicity of AZD7798 following administration of single ascending doses will be assessed. Day 1 to Day 8, and Days 15, 22, 29, 43, 57, and 85
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1